Immunovant, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eric Venker
- Full Time Employees
- 362
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 320 West 37th Street New York City NY United States of America 10018
- IPO Date
- Jun 21, 2019
- CIK
- 0001764013
- Website
- immunovant.com
- Similar Companies
- Business
- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company, develops fully human monoclonal antibodies that target the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies in autoimmune diseases. Founded in 2018 and headquartered in New York, the company focuses on immunology segments including endocrinology, rheumatology, neurology, and dermatology, with operations primarily in the United States. Its lead product candidate, IMVT-1402, advances in multiple potentially registrational trials for Graves' disease, rheumatoid arthritis (including ACPA+ difficult-to-treat RA), myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus, and Sjögren’s disease; batoclimab progresses in Phase 2/3 studies for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, and Graves' disease. Recent developments include FDA clearance of five IND applications for IMVT-1402, initiation of proof-of-concept studies in cutaneous lupus erythematosus and Sjögren’s disease in 2025, completion of enrollment in the batoclimab CIDP Phase 2b trial with data expected by March 2025, a $450 million private placement in January 2025 to fund pipeline advancement, and plans for 11 registration-enabling trials by 2026 alongside potential therapy launches in 2026-2027.
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
Immunovant Stock Surges Despite Disappointing Earnings Miss
Immunovant Q4 Earnings Call Highlights
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock
Financial Analysis: Arcus Biosciences (NYSE:RCUS) vs. Immunovant (NASDAQ:IMVT)
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
Immunovant's treatment for eye disease fails late-stage trial
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Strong Earnings